Cooper Companies (NASDAQ:COO) Director Acquires $136,780.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Erik Kurzius acquired 2,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the purchase, the director directly owned 5,777 shares in the company, valued at $395,089.03. This trade represents a 52.95% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cooper Companies Trading Down 0.7%

Shares of Cooper Companies stock opened at $68.07 on Thursday. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $109.37. The stock’s 50-day simple moving average is $69.86 and its 200 day simple moving average is $74.30. The stock has a market capitalization of $13.53 billion, a P/E ratio of 33.53, a P/E/G ratio of 1.80 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the business posted $0.96 EPS. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a share buyback plan on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Caldwell Trust Co bought a new position in shares of Cooper Companies in the second quarter worth approximately $274,000. Orion Porfolio Solutions LLC increased its position in shares of Cooper Companies by 840.5% in the second quarter. Orion Porfolio Solutions LLC now owns 96,592 shares of the medical device company’s stock worth $6,873,000 after purchasing an additional 86,322 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of Cooper Companies by 116.5% in the second quarter. Squarepoint Ops LLC now owns 42,134 shares of the medical device company’s stock worth $2,998,000 after purchasing an additional 22,676 shares during the last quarter. State of Wyoming bought a new position in Cooper Companies during the second quarter valued at approximately $220,000. Finally, Westwood Holdings Group Inc. grew its position in Cooper Companies by 23.4% during the second quarter. Westwood Holdings Group Inc. now owns 311,745 shares of the medical device company’s stock valued at $22,184,000 after acquiring an additional 59,190 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus lowered their price objective on Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, August 28th. Wall Street Zen cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. BNP Paribas raised shares of Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. Morgan Stanley set a $76.00 price objective on shares of Cooper Companies and gave the company an “equal weight” rating in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $84.75.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.